home / stock / lptx / lptx quote
Last: | $2.80 |
---|---|
Change Percent: | -5.41% |
Open: | $2.99 |
Close: | $2.96 |
High: | $3.04 |
Low: | $2.77 |
Volume: | 167,798 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.8 | $2.99 | $2.96 | $3.04 | $2.77 | 167,798 | 04-19-2024 |
$2.96 | $2.99 | $2.96 | $3.06 | $2.89 | 101,757 | 04-18-2024 |
$3 | $2.94 | $3 | $3.135 | $2.9245 | 146,417 | 04-17-2024 |
$2.98 | $3.04 | $2.98 | $3.2 | $2.95 | 151,233 | 04-16-2024 |
$3 | $3.24 | $3 | $3.49 | $2.752 | 521,740 | 04-15-2024 |
$3.24 | $3.15 | $3.24 | $3.5 | $3.07 | 565,262 | 04-12-2024 |
$3.115 | $3.5 | $3.115 | $4.39 | $3.03 | 5,675,632 | 04-11-2024 |
$3.04 | $3.28 | $3.04 | $3.38 | $2.91 | 435,708 | 04-10-2024 |
$3.41 | $2.6 | $3.41 | $3.59 | $2.59 | 1,358,044 | 04-09-2024 |
$2.58 | $2.55 | $2.58 | $2.64 | $2.53 | 68,225 | 04-08-2024 |
$2.54 | $2.49 | $2.54 | $2.5732 | $2.45 | 67,432 | 04-05-2024 |
$2.51 | $2.57 | $2.51 | $2.655 | $2.42 | 95,092 | 04-04-2024 |
$2.53 | $2.6 | $2.53 | $2.6 | $2.42 | 128,899 | 04-03-2024 |
$2.63 | $2.75 | $2.63 | $2.75 | $2.58 | 83,983 | 04-02-2024 |
$2.75 | $2.69 | $2.75 | $2.75 | $2.55 | 153,697 | 04-01-2024 |
$2.66 | $2.82 | $2.66 | $2.9799 | $2.645 | 192,513 | 03-29-2024 |
$2.66 | $2.82 | $2.66 | $2.9799 | $2.645 | 192,513 | 03-28-2024 |
$2.78 | $2.5 | $2.78 | $2.8099 | $2.44 | 191,777 | 03-27-2024 |
$2.48 | $2.44 | $2.48 | $2.51 | $2.41 | 101,183 | 03-26-2024 |
$2.4 | $2.52 | $2.4 | $2.52 | $2.3212 | 276,900 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...